Name Marcel van | ||
 | ||
Fields Allogeneic Bone Marrow Transplantation, Hematology, Oncology, Immunology Institutions Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, Weill Graduate School of Medical Sciences Alma mater University of Leiden, The Netherlands | ||
Marcel R.M. van den Brink Top #5 Facts
Marcel R.M. van den Brink (born 1960) is a Dutch hematologist and researcher who is an expert in hematopoietic stem cell transplantation for cancer patients. He is Head of the Division of Hematologic Oncology, Alan Houghton Chair in Immunology, Attending Physician on the Adult Bone Marrow Transplantation Service, and Member at Memorial Sloan Kettering Cancer Center (MSKCC) in New York, New York. He holds joint appointments in Sloan-Kettering Institute's Immunology Program, the Department of Medicine at MSKCC, and is also Professor of Medicine and Immunology at Weill Cornell Graduate School of Medical Sciences.
Contents
As a physician-scientist, van den Brink studies allogeneic bone marrow transplantation both in the clinic and the laboratory. Major contributions include a) the development of strategies to enhance post-transplant immune reconstitution such as Interleukin-7, Keratinocyte Growth Factor, Sex Steroid Blockade, Interleukin-22 (IL-22), and adoptive cell therapy with precursor T cells and b) novel insights in the pathophysiology of graft-versus-host disease (GVHD) such as the role of T cell cytolytic pathways, intestinal homing molecules, donor-derived neovascularization, and more recently, intestinal microflora
Biography
Van den Brink obtained his M.D. and Ph.D. cum laude from the University of Leiden in the Netherlands. He completed a postdoctoral fellowship at The University of Pittsburgh Cancer Institute in Pittsburgh, Pennsylvania, and then completed an internship and residency at Duke University Medical Center in Durham, North Carolina. From 1994-1997, van den Brink was a Clinical Fellow in Hematology and Oncology at Beth Israel Deaconess Medical Center and a Clinical Fellow in Medicine at Harvard Medical School in Boston, Massachusetts. He completed a post-doctoral fellowship with Dr. Steven J. Burakoff, MD at the Dana-Farber Cancer Institute in Boston, MA from 1995-1999.
In 1999, van den Brink joined the Adult Allogeneic Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center and the Immunology Program at Sloan-Kettering Institute. He was jointly appointed at Weill Cornell Medical College in 2000. He then served as Chief of the Adult Allogeneic Bone Marrow Transplantation Service from 2004-2008 In 2008, van den Brink was named Head of the Division of Hematologic Oncology.
Awards
In recognition of his achievements, Dr. van den Brink has been awarded the Physician Scientist Award of the Howard Hughes Medical Institute, the Amy Strelzer Manasevit Scholar Award of the National Marrow Donor Program, and the Damon Runyon Scholar Award of the Cancer Research Fund, along with a scholarship from the V Foundation for Cancer Research. In 2004 he was elected to the American Society for Clinical Investigation and in 2013 to The Association of American Physicians. Dr. van den Brink was also instrumental in the development of the first genomic profiling assay for hematological malignancies called FoundationOne™ Heme.
Selected publications
